Biotech News

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Black Diamond Therapeutics (BDTX)Black Diamond Therapeutics2026-06-25 13:46 ESTConference / presentation

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca,

Open original release

Related news

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

BDTXBlack Diamond Therapeutics2026-06-25 13:46 EST

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

View all latest news

Black Diamond Therapeutics

Black Diamond Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

BDTXBlack Diamond Therapeutics2026-06-26 08:52 EST

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

BDTXBlack Diamond Therapeutics2026-06-26 08:52 EST

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

BDTXBlack Diamond Therapeutics2026-06-26 08:52 EST

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-06-26 08:52 EST

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

BDTXBlack Diamond Therapeutics2026-06-26 08:52 EST

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States